Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

NCT05061251 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Drug availability

Conditions

Glioma
IDH Mutation

Interventions

DRUG: BAY 2402234

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]